Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2012

Open Access 01-12-2012 | Research

Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies

Authors: Li Xuan, Fen Huang, Zhiping Fan, Hongsheng Zhou, Xian Zhang, Guopan Yu, Yu Zhang, Can Liu, Jing Sun, Qifa Liu

Published in: Journal of Hematology & Oncology | Issue 1/2012

Login to get access

Abstract

Background

Intensified conditioning regimens (increasing the intensity of standard myeloablative conditioning) for hematological malignancies in allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce the relapse rate of the underlying disease, but it might simultaneously increase the transplant-related mortality including the mortality of infections. To explore whether intensified conditioning affected Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections, 185 patients undergoing allo-HSCT were enrolled.

Methods

A total of 104 cases received standard and 81 intensified conditioning. Cyclosporine A (CsA) withdrawal and/or donor lymphocyte infusion (DLI) were conducted in high-risk patients. The EBV-DNA and CMV-DNA levels of blood were monitored regularly by quantitative real-time polymerase chain reaction (RQ-PCR) and immune reconstitution of recipients were analyzed by flow cytometry.

Results

The 3-year cumulative incidence of EBV viremia, EBV-associated diseases and mortality of EBV-associated diseases were 25.3% ± 4.6%, 10.5% ± 3.4% and 0.0% ± 0.0% in the standard group, compared with 45.6% ± 6.5%, 26.0% ±5.3% and 7.3% ± 3.1% in the intensified group (P = 0.002, P = 0.002, P = 0.008). The 3-year cumulative incidence of CMV viremia and CMV-associated diseases, mortality of CMV-associated diseases and incidence of bacterial and fungal infections were similar between the two groups (P = 0.855, P = 0.581, P = 0.933, P = 0.142, P = 0.182, respectively). Multivariate analysis showed that intensified conditioning was one of the risk factors for EBV viremia and EBV-associated diseases (P = 0.037, P = 0.037), but it had no effects on CMV infections. The percentage of CD4+ T cells and CD4+/CD8+ ratio at 3 months post-transplantation were lower in the intensified group (P = 0.032, P = 0.022). The 3-year OS and DFS in the standard group were 62.2% ± 5.8% and 60.6% ± 5.6%, compared with 51.6% ± 6.2% and 51.1% ± 5.9% in the intensified group (P = 0.029, P = 0.063).

Conclusions

Intensified conditioning represents a promising approach for high-risk hematological malignancies, although it affects early immune reconstitution of recipients and increases the incidence and mortality of EBV infections.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ: Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006, 108: 1092-1099. 10.1182/blood-2005-10-4165.CrossRefPubMed Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ: Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006, 108: 1092-1099. 10.1182/blood-2005-10-4165.CrossRefPubMed
2.
go back to reference Lv M, Huang X: Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. J Hematol Oncol. 2012, 5: 10-10.1186/1756-8722-5-10.PubMedCentralCrossRefPubMed Lv M, Huang X: Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. J Hematol Oncol. 2012, 5: 10-10.1186/1756-8722-5-10.PubMedCentralCrossRefPubMed
3.
go back to reference Martin-Pena A, Aguilar-Guisado M, Espigado I, Parody R, Miguel Cisneros J: Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. Clin Transplant. 2011, 25: 468-474. 10.1111/j.1399-0012.2010.01286.x.CrossRefPubMed Martin-Pena A, Aguilar-Guisado M, Espigado I, Parody R, Miguel Cisneros J: Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. Clin Transplant. 2011, 25: 468-474. 10.1111/j.1399-0012.2010.01286.x.CrossRefPubMed
4.
go back to reference Mato AR, Morgans A, Luger SM: Novel strategies for relapsed and refractory acute myeloid leukemia. Curr Opin Hematol. 2008, 15: 108-114. 10.1097/MOH.0b013e3282f463d2.CrossRefPubMed Mato AR, Morgans A, Luger SM: Novel strategies for relapsed and refractory acute myeloid leukemia. Curr Opin Hematol. 2008, 15: 108-114. 10.1097/MOH.0b013e3282f463d2.CrossRefPubMed
5.
go back to reference Ringden O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R, Sierra J, Gorin NC: A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 1996, 93: 637-645. 10.1046/j.1365-2141.1996.d01-1681.x.CrossRefPubMed Ringden O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R, Sierra J, Gorin NC: A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 1996, 93: 637-645. 10.1046/j.1365-2141.1996.d01-1681.x.CrossRefPubMed
6.
go back to reference Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R: Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001, 97: 631-637. 10.1182/blood.V97.3.631.CrossRefPubMed Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R: Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001, 97: 631-637. 10.1182/blood.V97.3.631.CrossRefPubMed
7.
go back to reference McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001, 97: 3390-3400. 10.1182/blood.V97.11.3390.CrossRefPubMed McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001, 97: 3390-3400. 10.1182/blood.V97.11.3390.CrossRefPubMed
8.
go back to reference Gurman G, Arat M, Ilhan O, Konuk N, Beksac M, Celebi H, Ozcan M, Arslan O, Ustun C, Akan H, Uysal A, Koc H: Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Cytotherapy. 2001, 3: 253-260. 10.1080/146532401317070880.CrossRefPubMed Gurman G, Arat M, Ilhan O, Konuk N, Beksac M, Celebi H, Ozcan M, Arslan O, Ustun C, Akan H, Uysal A, Koc H: Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Cytotherapy. 2001, 3: 253-260. 10.1080/146532401317070880.CrossRefPubMed
9.
go back to reference Gutierrez-Aguirre CH, Cantu-Rodriguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-Gonzalez O, Jaime-Perez JC, Morales-Toquero A, Tarin-Arzaga LC, Ruiz-Arguelles GJ, Gomez-Almaguer D: Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology. 2007, 12: 193-197. 10.1080/10245330701214285.CrossRefPubMed Gutierrez-Aguirre CH, Cantu-Rodriguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-Gonzalez O, Jaime-Perez JC, Morales-Toquero A, Tarin-Arzaga LC, Ruiz-Arguelles GJ, Gomez-Almaguer D: Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology. 2007, 12: 193-197. 10.1080/10245330701214285.CrossRefPubMed
10.
go back to reference Aschan J: Risk assessment in haematopoietic stem cell transplantation: conditioning. Best Pract Res Clin Haematol. 2007, 20: 295-310. 10.1016/j.beha.2006.09.004.CrossRefPubMed Aschan J: Risk assessment in haematopoietic stem cell transplantation: conditioning. Best Pract Res Clin Haematol. 2007, 20: 295-310. 10.1016/j.beha.2006.09.004.CrossRefPubMed
11.
go back to reference Engelhard D, Elishoov H, Or R, Naparstek E, Nagler A, Strauss N, Cividalli G, Aker M, Ramu N, Simhon A: Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant. 1995, 16: 565-570.PubMed Engelhard D, Elishoov H, Or R, Naparstek E, Nagler A, Strauss N, Cividalli G, Aker M, Ramu N, Simhon A: Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant. 1995, 16: 565-570.PubMed
12.
go back to reference Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W: Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica. 2002, 87: 52-58.PubMed Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W: Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica. 2002, 87: 52-58.PubMed
13.
go back to reference Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H: Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant. 2009, 15: 1376-1385. 10.1016/j.bbmt.2009.06.017.CrossRefPubMed Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H: Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant. 2009, 15: 1376-1385. 10.1016/j.bbmt.2009.06.017.CrossRefPubMed
14.
go back to reference Liu YC, Lu PL, Hsiao HH, Chang CS, Liu TC, Yang WC, Lin SF: Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Ann Hematol. 2012, 91: 587-595. 10.1007/s00277-011-1351-8.CrossRefPubMed Liu YC, Lu PL, Hsiao HH, Chang CS, Liu TC, Yang WC, Lin SF: Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Ann Hematol. 2012, 91: 587-595. 10.1007/s00277-011-1351-8.CrossRefPubMed
15.
go back to reference Ljungman P, Griffiths P, Paya C: Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002, 34: 1094-1097. 10.1086/339329.CrossRefPubMed Ljungman P, Griffiths P, Paya C: Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002, 34: 1094-1097. 10.1086/339329.CrossRefPubMed
16.
go back to reference Meijer E, Cornelissen JJ: Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol. 2008, 15: 576-585. 10.1097/MOH.0b013e328311f438.CrossRefPubMed Meijer E, Cornelissen JJ: Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol. 2008, 15: 576-585. 10.1097/MOH.0b013e328311f438.CrossRefPubMed
17.
go back to reference Liu QF, Fan ZP, Luo XD, Sun J, Zhang Y, Ding YQ: Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. Transpl Infect Dis. 2010, 12: 284-291. 10.1111/j.1399-3062.2010.00502.x.CrossRefPubMed Liu QF, Fan ZP, Luo XD, Sun J, Zhang Y, Ding YQ: Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. Transpl Infect Dis. 2010, 12: 284-291. 10.1111/j.1399-3062.2010.00502.x.CrossRefPubMed
18.
go back to reference Jaskula E, Dlubek D, Sedzimirska M, Duda D, Tarnowska A, Lange A: Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation. Transplant Proc. 2010, 42: 3273-3276. 10.1016/j.transproceed.2010.07.027.CrossRefPubMed Jaskula E, Dlubek D, Sedzimirska M, Duda D, Tarnowska A, Lange A: Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation. Transplant Proc. 2010, 42: 3273-3276. 10.1016/j.transproceed.2010.07.027.CrossRefPubMed
19.
go back to reference Olkinuora H, von Willebrand E, Kantele JM, Vainio O, Talvensaari K, Saarinen-Pihkala U, Siitonen S, Vettenranta K: The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. Scand J Immunol. 2011, 73: 586-593. 10.1111/j.1365-3083.2011.02530.x.CrossRefPubMed Olkinuora H, von Willebrand E, Kantele JM, Vainio O, Talvensaari K, Saarinen-Pihkala U, Siitonen S, Vettenranta K: The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. Scand J Immunol. 2011, 73: 586-593. 10.1111/j.1365-3083.2011.02530.x.CrossRefPubMed
20.
go back to reference Kim SY, Lee DG, Kim MS, Kim HJ, Lee S, Min CK: The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease. Am J Hematol. 2008, 83: 784-788. 10.1002/ajh.21227.CrossRefPubMed Kim SY, Lee DG, Kim MS, Kim HJ, Lee S, Min CK: The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease. Am J Hematol. 2008, 83: 784-788. 10.1002/ajh.21227.CrossRefPubMed
21.
go back to reference Reddy N, Rezvani K, Barrett AJ, Savani BN: Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant. 2011, 17: 591-597. 10.1016/j.bbmt.2010.08.007.PubMedCentralCrossRefPubMed Reddy N, Rezvani K, Barrett AJ, Savani BN: Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant. 2011, 17: 591-597. 10.1016/j.bbmt.2010.08.007.PubMedCentralCrossRefPubMed
22.
go back to reference Jimenez M, Ercilla G, Martinez C: Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens. Leukemia. 2007, 21: 1628-1637. 10.1038/sj.leu.2404681.CrossRefPubMed Jimenez M, Ercilla G, Martinez C: Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens. Leukemia. 2007, 21: 1628-1637. 10.1038/sj.leu.2404681.CrossRefPubMed
23.
go back to reference Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Little MT, Corey L, Storb R: Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002, 99: 1978-1985. 10.1182/blood.V99.6.1978.CrossRefPubMed Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Little MT, Corey L, Storb R: Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002, 99: 1978-1985. 10.1182/blood.V99.6.1978.CrossRefPubMed
24.
go back to reference Suminoe A, Matsuzaki A, Koga Y, Kusuhara K, Hara T: Human herpesvirus 6 (HHV-6)-associated pleurisy after unrelated cord blood transplantation in children with chemotherapy-resistant malignant Lymphoma. J Pediatr Hematol Oncol. 2007, 29: 709-712. 10.1097/MPH.0b013e318142b50d.CrossRefPubMed Suminoe A, Matsuzaki A, Koga Y, Kusuhara K, Hara T: Human herpesvirus 6 (HHV-6)-associated pleurisy after unrelated cord blood transplantation in children with chemotherapy-resistant malignant Lymphoma. J Pediatr Hematol Oncol. 2007, 29: 709-712. 10.1097/MPH.0b013e318142b50d.CrossRefPubMed
25.
go back to reference Peres RM, Costa CR, Andrade PD, Bonon SH, Albuquerque DM, de Oliveira C, Vigorito AC, Aranha FJ, de Souza CA, Costa SC: Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR. BMC Infect Dis. 2010, 10: 147-10.1186/1471-2334-10-147.PubMedCentralCrossRefPubMed Peres RM, Costa CR, Andrade PD, Bonon SH, Albuquerque DM, de Oliveira C, Vigorito AC, Aranha FJ, de Souza CA, Costa SC: Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR. BMC Infect Dis. 2010, 10: 147-10.1186/1471-2334-10-147.PubMedCentralCrossRefPubMed
26.
go back to reference Swerdlow SH, Webber SA, Chadburn A, Ferry JA: Post-transplant lymphoproliferative disorders. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008, IARC Press, Lyon, 343-349. Swerdlow SH, Webber SA, Chadburn A, Ferry JA: Post-transplant lymphoproliferative disorders. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008, IARC Press, Lyon, 343-349.
27.
go back to reference Wagner HJ, Rooney CM, Heslop HE: Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002, 8: 1-8. 10.1053/bbmt.2002.v8.pm11846351.CrossRefPubMed Wagner HJ, Rooney CM, Heslop HE: Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002, 8: 1-8. 10.1053/bbmt.2002.v8.pm11846351.CrossRefPubMed
28.
go back to reference Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, Ljungman P, Engelhard D: Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009, 43: 757-770. 10.1038/bmt.2008.386.CrossRefPubMed Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, Ljungman P, Engelhard D: Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009, 43: 757-770. 10.1038/bmt.2008.386.CrossRefPubMed
29.
go back to reference Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K: Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis. 2007, 39: 235-244. 10.1080/00365540600978906.CrossRefPubMed Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K: Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis. 2007, 39: 235-244. 10.1080/00365540600978906.CrossRefPubMed
30.
go back to reference Mineishi S, Longo WL, Atkinson ME, Smith EP, Hamielec M, Wiersma SR, Kinsella TJ, Schuening FG: Addition of high-dose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. Bone Marrow Transplant. 1999, 23: 1217-1222. 10.1038/sj.bmt.1701793.CrossRefPubMed Mineishi S, Longo WL, Atkinson ME, Smith EP, Hamielec M, Wiersma SR, Kinsella TJ, Schuening FG: Addition of high-dose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. Bone Marrow Transplant. 1999, 23: 1217-1222. 10.1038/sj.bmt.1701793.CrossRefPubMed
31.
go back to reference de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S: Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004, 104: 865-872. 10.1182/blood-2003-11-3750.CrossRefPubMed de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S: Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004, 104: 865-872. 10.1182/blood-2003-11-3750.CrossRefPubMed
32.
go back to reference Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K, Goldstone AH, Linch DC, Mackinnon S: Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004, 103: 1548-1556.CrossRefPubMed Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K, Goldstone AH, Linch DC, Mackinnon S: Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004, 103: 1548-1556.CrossRefPubMed
33.
go back to reference Frere P, Baron F, Bonnet C, Hafraoui K, Pereira M, Willems E, Fillet G, Beguin Y: Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2006, 37: 411-418. 10.1038/sj.bmt.1705255.CrossRefPubMed Frere P, Baron F, Bonnet C, Hafraoui K, Pereira M, Willems E, Fillet G, Beguin Y: Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2006, 37: 411-418. 10.1038/sj.bmt.1705255.CrossRefPubMed
34.
go back to reference Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, Einsele H, Cordonnier C: Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005, 36: 757-769. 10.1038/sj.bmt.1705140.CrossRefPubMed Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, Einsele H, Cordonnier C: Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005, 36: 757-769. 10.1038/sj.bmt.1705140.CrossRefPubMed
35.
go back to reference Omar H, Hagglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringden O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P: Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis. 2009, 11: 393-399. 10.1111/j.1399-3062.2009.00410.x.CrossRefPubMed Omar H, Hagglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringden O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P: Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis. 2009, 11: 393-399. 10.1111/j.1399-3062.2009.00410.x.CrossRefPubMed
36.
go back to reference Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE: Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009, 113: 4992-5001. 10.1182/blood-2008-09-178046.PubMedCentralCrossRefPubMed Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE: Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009, 113: 4992-5001. 10.1182/blood-2008-09-178046.PubMedCentralCrossRefPubMed
37.
go back to reference Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA, Wagner JE: Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006, 108: 2874-2880. 10.1182/blood-2006-03-011791.PubMedCentralCrossRefPubMed Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA, Wagner JE: Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006, 108: 2874-2880. 10.1182/blood-2006-03-011791.PubMedCentralCrossRefPubMed
38.
go back to reference Wu XL, Liu QF: Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation. J Hematol Oncol. 2012, 5 (Suppl 1): A8-10.1186/1756-8722-5-S1-A8.PubMedCentralCrossRef Wu XL, Liu QF: Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation. J Hematol Oncol. 2012, 5 (Suppl 1): A8-10.1186/1756-8722-5-S1-A8.PubMedCentralCrossRef
Metadata
Title
Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies
Authors
Li Xuan
Fen Huang
Zhiping Fan
Hongsheng Zhou
Xian Zhang
Guopan Yu
Yu Zhang
Can Liu
Jing Sun
Qifa Liu
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-5-46

Other articles of this Issue 1/2012

Journal of Hematology & Oncology 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine